Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.

Terguride, the C9-10 dihydrogenated derivative of lisuride, is a new drug which inhibits pituitary prolactin (PRL) secretion. It has mixed dopaminergic-antidopaminergic and alpha 2-antiadrenergic activity, and has proved useful in the clinical management of hyperprolactinemia. However, no trial comp...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Ciccarelli, E, Touzel, R, Besser, M, Grossman, A
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	1988

Míreanna comhchosúla

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1987)

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
de réir: Verhelst, J, et al.
Foilsithe / Cruthaithe: (1991)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
de réir: Marianne F. Clausen, et al.
Foilsithe / Cruthaithe: (2021-12-01)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1986)

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
de réir: Ciccarelli, E, et al.
Foilsithe / Cruthaithe: (1989)

Glucose Intolerance Induced by Oligemic Brain Hypoxia: The Effect of Terguride
de réir: Věroslav Golda, et al.
Foilsithe / Cruthaithe: (1997-01-01)

Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia
de réir: Harish Kumar V.S., et al.
Foilsithe / Cruthaithe: (2013-09-01)

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
de réir: O A Gerasimenko, et al.
Foilsithe / Cruthaithe: (2011-12-01)

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
de réir: G. Tavares, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy.
de réir: Jenkins, P, et al.
Foilsithe / Cruthaithe: (1996)

Two new dopamine agonists that are long acting in vivo but short acting in vitro.
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1980)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1985)

The Dark Side of Dopamine Agonist Therapy in Prolactinoma Management
de réir: Sonia Ananthakrishnan, MD
Foilsithe / Cruthaithe: (2017-01-01)

A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease.
de réir: Hale, A, et al.
Foilsithe / Cruthaithe: (1988)

Hyperprolactinemia in Obese as Well as in Lean Females of Koletsky Rats: Effect of Long Lasting Terguride Treatment
de réir: Věroslav Golda, et al.
Foilsithe / Cruthaithe: (1998-01-01)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
de réir: Sinn, D, et al.
Foilsithe / Cruthaithe: (1985)

Cabergoline or bromocriptine for prolactinoma?
de réir: Nicolás Triantafilo, et al.
Foilsithe / Cruthaithe: (2016-09-01)

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
de réir: Ismail, I.S., et al.
Foilsithe / Cruthaithe: (1994)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
de réir: Xiaoan Ke, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Central Hyperthermia Treated with Bromocriptine
de réir: P. Natteru, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Bromocriptine in the Management of Central Hyperthermia
de réir: Krishnaprasad Narayanankutty, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Repurposing of Bromocriptine for Cancer Therapy
de réir: Ean-Jeong Seo, et al.
Foilsithe / Cruthaithe: (2018-10-01)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
de réir: A Ahmadi Ahangar, et al.
Foilsithe / Cruthaithe: (2002-07-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
de réir: Michael A Via, et al.
Foilsithe / Cruthaithe: (2010-03-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
de réir: Via MA
Foilsithe / Cruthaithe: (2010-03-01)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
de réir: Mohammad Edrees Mohammad, et al.
Foilsithe / Cruthaithe: (2021-01-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
de réir: Xiaoshuang Liu, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Effect of Long Lasting Terguride Treatment on Mutual Relationship Between Glycide and Lipid Parameters in SHR/N-cp Koletsky Rats
de réir: Věroslav Golda, et al.
Foilsithe / Cruthaithe: (1998-01-01)

Bromocriptine for type 2 diabetes mellitus
de réir: Ooi, Cheow Peng, et al.
Foilsithe / Cruthaithe: (2013)

Bromocriptine in type 2 diabetes mellitus
de réir: C Shivaprasad, et al.
Foilsithe / Cruthaithe: (2011-01-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
de réir: Kaltsas, G, et al.
Foilsithe / Cruthaithe: (2004)

Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?
de réir: Guido eFrank
Foilsithe / Cruthaithe: (2014-11-01)

Two new dopamine agonists that are long acting in vivo but short acting in vitro
de réir: Grossman, A, et al.
Foilsithe / Cruthaithe: (1980)

The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors.
de réir: Ribeiro-Oliveira, A, et al.
Foilsithe / Cruthaithe: (2008)

Dopamine Agonists and Pathologic Behaviors
de réir: Brendan J. Kelley, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
de réir: Satoko Sumi, et al.
Foilsithe / Cruthaithe: (2022-09-01)

Bromocriptine use is associated with decreased smoking rates.
de réir: Murphy, M, et al.
Foilsithe / Cruthaithe: (2002)

A peripartum cardiomyopathy case treated with bromocriptine
de réir: Dilek Yeşilbursa, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Bromocriptine and insulin sensitivity in lean and obese subjects
de réir: L Bahler, et al.
Foilsithe / Cruthaithe: (2016-11-01)